Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee

  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Markt vandaag Koersen Forum Premium IEX Expert
Home  /  Forum  /  Acacia Pharma  /  Waar beleggen jullie nog meer in

Acacia Pharma« Terug naar discussie overzicht

Waar beleggen jullie nog meer in

Volgen
2.693 Posts
Pagina: «« 1 ... 60 61 62 63 64 ... 135 »» | Laatste | Omlaag ↓
  1. forum rang 5 Hulskof 29 februari 2020 18:32
    South Korea has reported 813 new coronavirus cases, bringing the country’s total infections to 3,150, the Korea Centers for Disease Control and Prevention said on Saturday.
    That's a record daily increase in infections since South Korea confirmed its first patient, on January 20. South Korea is calling this a critical moment for containing the spread.
    Large swathes of Seoul and other cities appear to be largely deserted.

    seekingalpha.com/news/3547240?source=...

    Dalen kan dus mogelijk nog even doorgaan...
  3. [verwijderd] 29 februari 2020 21:29
    quote:

    Hulskof schreef op 29 februari 2020 18:32:

    South Korea has reported 813 new coronavirus cases, bringing the country’s total infections to 3,150, the Korea Centers for Disease Control and Prevention said on Saturday.
    That's a record daily increase in infections since South Korea confirmed its first patient, on January 20. South Korea is calling this a critical moment for containing the spread.
    Large swathes of Seoul and other cities appear to be largely deserted.

    seekingalpha.com/news/3547240?source=...

    Dalen kan dus mogelijk nog even doorgaan...
    ik vrees er ook voor; trouwens, in Europa zijn er nu nog weinig slachtoffers (besmet), dit moet (en zal) nog komen

  5. forum rang 5 Hulskof 1 maart 2020 22:02
    quote:

    georgeramaut schreef op 1 maart 2020 21:40:

    Zijn er geen aandelen die omhoog gaan door corona
    Zoals Novacyt alhoewel we daar waarschijnlijk te laat zijn .
    Genoeg. Zie onderstaande lijst. Denk alleen dat je ook daar al veel te laat bent.

    It could also be another volatile week for companies perceived as coronavirus plays such as iBio (NYSEMKT:IBIO), Alpha Pro Tech (NYSEMKT:APT), Lakeland Industries (NASDAQ:LAKE), Vaxart (NASDAQ:VXRT), Co-Diagnostics (NASDAQ:CODX), Inovio Pharmaceuticals (NASDAQ:INO), Novavax (NASDAQ:NVAX), BioCryst Pharmaceuticals (NASDAQ:BCRX), Cocrystal Pharma (NASDAQ:OTC:COCP), Vir Biotechnology (NASDAQ:VIR), Moderna (NASDAQ:MRNA), Gilead Sciences (NASDAQ:GILD), Qiagen (NYSE:QGEN), Owens & Minor (NYSE:OMI), Altimmune ((NASDAQ:ALT) and Allied Healthcare Products (NASDAQ:AHPI)
  7. forum rang 5 Hulskof 2 maart 2020 13:38
    Heron verwacht een halvering van de CINV-omzet dit jaar om daarna de groei weer te hervatten. Klinkt niet best in mijn oren.

    CINV 2019 Net Product Sales: For the three months ended December 31, 2019, chemotherapy-induced nausea and vomiting (CINV) franchise net product sales were $35.1 million, up 22% from the same period in 2018. For the twelve months ended December 31, 2019, CINV franchise net product sales were $146.0 million, up 88% from the same period in 2018.
    CINVANTI® Net Product Sales: Net product sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2019 were $34.6 million and $132.2 million, respectively, compared to $23.4 million and $56.2 million, respectively, for the same periods in 2018.
    SUSTOL® Net Product Sales: Net product sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2019 were $0.5 million and $13.8 million, respectively, compared to $5.4 million and $21.3 million for the same periods in 2018. On October 1, 2019, the Company made a business decision to discontinue all discounting of SUSTOL, which resulted in significantly lower SUSTOL net product sales.
    2020 Net Product Sales Guidance: Heron expects 2020 net product sales for the CINV franchise of $70 million to $80 million and the CINV franchise to return to growth in 2021 and beyond.

    Verkopen laatste kwartaal vielen ook wat lager uit dan wat Heron tussentijds had aangegeven.
    Ik vermoed dat we hier verder op omlaag zullen gaan.

    herontherapeutics.gcs-web.com/news-re...
  8. [verwijderd] 2 maart 2020 14:45
    Heron was ergens te verwachten dit maar is nu gewoon wachten op het bovenste gedeelte van de pagina. HTX-011

    New Drug Application for HTX-011
    Contract Manufacturing Site for HTX-011
    Marketing Authorisation Application for HTX-011 in the European Union
    New Drug Submission for HTX-011 in Canada

    Ook wel goed met de cashpositie:

    As of December 31, 2019, Heron had cash, cash equivalents and short-term investments of $391.0 million compared to $332.4 million as of December 31, 2018. Net cash used for operating activities for the twelve months ended December 31, 2019 was $124.6 million, compared to $191.8 million for the same period in 2018. Heron expects that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2022.
  11. [verwijderd] 2 maart 2020 17:09
    On December 28, 2015, we entered into a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd., or BDB, for the use of the IFX-1 cell line in BDB’s development of drug candidates for sale in China. Pursuant to the agreement, we granted BDB an exclusive, non-transferable license to use the IFX-1 cell line and related intellectual property solely to develop and commercialize in China BDB’s drug candidates BDB-1 and BDB-2, as well as molecules that bind or interact with certain specified targets (“target-binding molecules”).
  14. [verwijderd] 2 maart 2020 20:58
    quote:

    Hulskof schreef op 2 maart 2020 13:38:

    Heron verwacht een halvering van de CINV-omzet dit jaar om daarna de groei weer te hervatten. Klinkt niet best in mijn oren.

    CINV 2019 Net Product Sales: For the three months ended December 31, 2019, chemotherapy-induced nausea and vomiting (CINV) franchise net product sales were $35.1 million, up 22% from the same period in 2018. For the twelve months ended December 31, 2019, CINV franchise net product sales were $146.0 million, up 88% from the same period in 2018.
    CINVANTI® Net Product Sales: Net product sales of CINVANTI (aprepitant) injectable emulsion for the three and twelve months ended December 31, 2019 were $34.6 million and $132.2 million, respectively, compared to $23.4 million and $56.2 million, respectively, for the same periods in 2018.
    SUSTOL® Net Product Sales: Net product sales of SUSTOL (granisetron) extended-release injection for the three and twelve months ended December 31, 2019 were $0.5 million and $13.8 million, respectively, compared to $5.4 million and $21.3 million for the same periods in 2018. On October 1, 2019, the Company made a business decision to discontinue all discounting of SUSTOL, which resulted in significantly lower SUSTOL net product sales.
    2020 Net Product Sales Guidance: Heron expects 2020 net product sales for the CINV franchise of $70 million to $80 million and the CINV franchise to return to growth in 2021 and beyond.

    Verkopen laatste kwartaal vielen ook wat lager uit dan wat Heron tussentijds had aangegeven.
    Ik vermoed dat we hier verder op omlaag zullen gaan.

    herontherapeutics.gcs-web.com/news-re...
    slechts nieuws, laagste koers was 15.68 .. toch geen reden voor mij om in paniek te verkopen, HTX-011 afwachten, cross the fingers
2.693 Posts
Pagina: «« 1 ... 60 61 62 63 64 ... 135 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Accsys 0,632 +0,01 +1,61%
Galapagos 26,740 +0,36 +1,36%
WDP 24,420 +0,30 +1,24%
Vopak 41,440 +0,46 +1,12%
Ahold Delhaize 30,770 +0,30 +0,98%
RELX 43,440 +0,32 +0,74%
ASML 721,200 +4,50 +0,63%
UNILEVER PLC 58,140 +0,36 +0,62%
CM.COM 6,600 +0,04 +0,61%
PROSUS 33,865 +0,20 +0,59%
KPN 3,647 +0,02 +0,58%
SHELL PLC 30,975 +0,18 +0,57%
DSM FIRMENICH AG 117,050 +0,60 +0,52%
EXOR NV 97,950 +0,50 +0,51%
ASMI 564,400 +2,60 +0,46%
Pharming 0,688 +0,00 +0,29%
Wolters Kluwer 156,050 +0,40 +0,26%
AEX 899,80 +2,25 +0,25%
NSI 20,900 +0,05 +0,24%
HEIJMANS KON 24,200 +0,05 +0,21%
Brunel 8,630 +0,01 +0,12%
UMG 22,770 +0,02 +0,09%
ACOMO 17,420 0,00 0,00%
Arcadis 63,400 0,00 0,00%
Nedap N.V. 56,600 0,00 0,00%
TKH 36,920 0,00 0,00%
Vastned 23,950 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
BESI 107,000 -4,60 -4,12%
Air France-KLM 8,500 -0,33 -3,72%
ABN AMRO BANK N.V. 15,945 -0,44 -2,69%
AZERION 1,540 -0,04 -2,53%
ING 16,318 -0,37 -2,22%
Sligro 12,200 -0,22 -1,77%
ADYEN NV 1.363,600 -20,20 -1,46%
RANDSTAD NV 43,360 -0,64 -1,45%
FASTNED 18,040 -0,26 -1,42%
AMG Critical Materials N.V. 15,660 -0,22 -1,39%
ArcelorMittal 21,210 -0,28 -1,30%
TomTom 5,130 -0,06 -1,16%
ALLFUNDS GROUP 5,210 -0,06 -1,14%
Sif Holding 14,360 -0,16 -1,10%
Avantium 1,850 -0,02 -1,07%
EBUSCO HOLDING 0,778 -0,01 -1,02%
ASR Nederland 43,000 -0,44 -1,01%
THEON INTERNAT 10,600 -0,10 -0,93%
PostNL 1,193 -0,01 -0,91%
JDE PEET'S 18,340 -0,16 -0,86%
Aegon 5,564 -0,05 -0,82%
SBM Offshore 16,360 -0,13 -0,79%
Fagron 18,540 -0,14 -0,75%
Van Lanschot Kempen NV 42,200 -0,30 -0,71%
AALBERTS NV 34,680 -0,24 -0,69%
RENEWI 7,600 -0,05 -0,65%
B&S Group SA 4,640 -0,03 -0,64%
Philips Koninklijke 27,280 -0,16 -0,58%
NX FILTRATION 4,390 -0,03 -0,57%
SIGNIFY NV 20,440 -0,10 -0,49%
Fugro 20,840 -0,10 -0,48%
OCI 26,060 -0,12 -0,46%
JUST EAT TAKEAWAY 12,575 -0,06 -0,44%
NN Group 44,750 -0,19 -0,42%
Eurocommercial Properties 25,450 -0,10 -0,39%
Basic-Fit 22,220 -0,08 -0,36%
Kendrion 11,820 -0,04 -0,34%
ASCX 1.194,59 -3,90 -0,33%
Heineken 79,020 -0,24 -0,30%
IMCD 152,100 -0,40 -0,26%
AMX 880,19 -2,16 -0,24%
Aperam 24,580 -0,06 -0,24%
Akzo Nobel 58,160 -0,14 -0,24%
BAM 3,796 -0,01 -0,21%
Corbion 23,540 -0,04 -0,17%
Alfen N.V. 12,165 -0,02 -0,16%
ForFarmers 3,150 0,00 -0,16%
Wereldhave 14,800 -0,02 -0,13%
CTP 16,280 -0,02 -0,12%
INPOST 17,080 -0,02 -0,12%
Flow Traders 17,870 -0,02 -0,11%
vlag naam koers verschil relatief verschil
AEX 899,93 +2,38 +0,27%
AEX GR 3.515,52 +8,17 +0,23%
Germany40^ 18.772,20 +52,19 +0,28%
FTSE 100 8.227,90 -2,09 -0,03%
EURO50 4.870,36 -2,85 -0,06%
US30^ 42.076,90 +10,90 +0,03%
Nasd100^ 19.833,00 +38,60 +0,20%
US500^ 5.710,68 +7,90 +0,14%
Japan225^ 38.257,00 +41,10 +0,11%
VD-NEW 15,08 +0,88 +6,20%
#/^ Index indications calculated real time, zie disclaimer